Synergy (SGYP) Higher After Plecanatide Meets Endpoints
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/26/2026
- US stock futures subdued in run-up to Nvidia results, inflation print
- Oil settles down more than 3%; investors shrug off US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Boston Scientific discloses cybersecurity incident causing global disruption
- Wall Street ends higher as tech rebounds before Nvidia results
- Six Flags to move headquarters from Charlotte to Arlington, Texas
- Intuit (INTU) Tops Q4 EPS; Offers FY27 Guidance
- Oppenheimer Upgrades Capricor Therapeutics (CAPR) to Outperform 'on Approval Optimism'
Synergy Pharmaceuticals (SGYP) PT Nearly Doubled at Cantor Fitzgerald
January 2, 2013 12:44 PM ESTCantor Fitzgerald raised its price target on Buy-rated Synergy Pharmaceuticals (NASDAQ: SGYP) from $7 to $13 following positive top-line results from its Phase IIb/III chronic constipation (CC) trial of plecanatide.
The firm comments, "While details were not disclosed since the company is attempting to... More
